Pharma’s reputational high will be short-lived
World of DTC Marketing
MARCH 17, 2021
Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028.
Let's personalize your content